What is Genemod?
Genemod operates at the intersection of biotechnology and enterprise software, providing a robust cloud-based platform designed to optimize inventory management and research collaboration. The company serves a critical need for life scientists and researchers who require sophisticated tools to manage reagents, track experimental data, and coordinate complex workflows. By integrating seamlessly into the operations of leading institutions such as the Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Genemod has established itself as a vital partner in the drug discovery pipeline. Its software solutions are engineered to reduce operational friction, allowing researchers to focus on the development of next-generation therapies with greater efficiency and precision.
How much funding has Genemod raised?
Genemod has raised a total of $7.7M across 3 funding rounds:
Other Financing Round
$1.5M
Angel/Seed
$1.7M
Angel/Seed
$4.5M
Other Financing Round (2020): $1.5M, investors not publicly disclosed
Angel/Seed (2020): $1.7M led by Defy.vc, Unpopular Ventures, Canaan Partners, Omicron, and Underdog Labs
Angel/Seed (2023): $4.5M supported by Defy, LDV Partners, Dolby Family Ventures, and Vulcan Medical Ventures
Key Investors in Genemod
Defy VC
Defy VC is an early-stage venture capital firm dedicated to supporting authentic founders in building enduring companies by focusing on innovative ideas that challenge the status quo.
LDV Partners
LDV Partners provides strategic insights and hands-on support to foster growth in disruptive technologies, with a portfolio that includes advancements in AI and life sciences.
Dolby Family Ventures
Dolby Family Ventures focuses on early-stage companies addressing significant science and engineering challenges, particularly within the biotech and pharmaceutical sectors.
What's next for Genemod?
Looking ahead, Genemod is poised to leverage its recent funding to expand its market footprint and enhance its product suite. The company's strategic roadmap likely involves deepening its integration capabilities and scaling its platform to support larger, multi-site research organizations. As the demand for digital transformation in pre-clinical research continues to rise, Genemod's focus on technologically advanced, scalable software positions it to capture significant market share. The ongoing support from high-profile venture partners suggests a long-term commitment to building an enduring enterprise that could fundamentally alter how life science organizations manage their research assets and accelerate the path to clinical breakthroughs.
See full Genemod company page
